CD4 and systemic lupus erythematosus: Thus, it will be interesting to elucidate through future studies whether this effect of Rituximab in SLE patients is mediated by an enhancement of the functional capability of CD4+CD25+ cells or by increasing the sensitivity of effector CD4+CD25- lymphocytes to regulatory signals.